GlassScriptPhysician profile
John Patrick Slater
NPI 1316584873
$2,378.11
in general payments reported to CMS, 2019-2025
21 companies · $532 in 2025
The $532 reported for 2025 was more than what 78% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $61.50 · 2022: $340 · 2023: $677 · 2024: $768 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,976.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $855.39 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Kestra Medical Technology Services, INC. | $231.53 | 2023-2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $218.08 | 2021-2022 | |
| Amgen INC. | $162.01 | 2023-2024 | Repatha |
| Abbott Laboratories | $150.14 | 2024-2025 | Mitraclip, Perclose Prostyle |
| Astrazeneca Pharmaceuticals LP | $149.59 | 2022-2024 | Farxiga, Wainua |
| Kiniksa Pharmaceuticals, LTD. | $95.26 | 2022-2023 | Arcalyst |
| Pfizer INC. | $94.04 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $73.40 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.83 | 2023 | Jardiance |
| Merck Sharp & Dohme LLC | $47.79 | 2022-2025 | Winrevair |
| Cvrx, INC. | $33.72 | 2025 | Barostim Neo System |
| Boston Scientific Corporation | $30.35 | 2024 | Watchman Flx |
| Lexicon Pharmaceuticals, INC. | $30.18 | 2024 | |
| W. L. Gore & Associates, INC. | $30.13 | 2023 | Gore Cardioform Septal Occluder |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $23.09 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $21.85 | 2023 | Camzyos |
| Scpharmaceuticals INC. | $18.82 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.19 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $16.92 | 2024 | Arcalyst |
| Chiesi USA, INC. | $13.80 | 2023 | Cleviprex, Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Slater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.